Clinical Trials Browser

Solid Tumors

NCT06233942 2026-03-18

Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors

Phase 1 Recruiting

308 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT03074513 2026-03-11

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

Phase 2 Active not recruiting

133 enrolled

DermatologicEndocrineHead & NeckOther solid neoplasmThoracic

Nasopharyngeal Carcinoma, Mesothelioma, Malignant, Adenocarcinoma, Mucinous, Adenoma, Islet Cell, Nasopharyngeal Neoplasms, Carcinoma, Merkel Cell, Carcinoma, Neuroendocrine

NCT07111546 2026-03-11

A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)]

Phase 2 Recruiting

140 enrolled

Other solid neoplasm

Advanced Solid Tumour

NCT04262466 2026-03-06

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

Phase 1/2 Active not recruiting

410 enrolled

Other solid neoplasm

Select Advanced Solid Tumors

NCT05579366 2026-03-03

RAINFOL-01

Phase 1/2 Recruiting

764 enrolled

BreastGynecologicOther solid neoplasmThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Fallopian Tube Neoplasms, Mesothelioma, Ovarian Neoplasms, Uterine Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

Clinical Trials

aCCeleR8-001

Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)]

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

RAINFOL-01

A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors

First In Human Study of CX-2051 in Advanced Solid Tumors

A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]

A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors

COMBINE-EGFR-1

A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.

A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors

A Study of SHR-4375 Injection in Combination With Other Antitumor Therapies in Patients With Solid Tumors

A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors

M9466 in Combination With Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511)

Chemotherapy Combined With Bevacizumab Neoadjuvant Therapy for HER2-negative Breast Cancer

A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin

A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors

A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors

A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors

HS-20089 Combination Treatment in Subjects With Advanced Solid Tumors

KD6001 in Combination With Anti-PD-1 Antibody±Bevacizumab in Patients With Advanced HCC and Other Solid Tumors

MiST

PD-1 Inhibitor Combined With Bevacizumab and FOLFIRI Regimen in the Second-line Treatment of Advanced Colorectal Cancer

A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors

VITAC

Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma

Combination of Bevacizumab and Allogeneic NK Immunotherapy for Metastatic Solid Tumors

Imatinib, Bevacizumab, and Cyclophosphamide in Patients With Refractory Metastatic Solid Tumors

Alternative Dosing for CRLX101(NLG207) Alone, With Avastin and With mFOLFOX6 in Advanced Solid Tumors

Study of TRC105 Combined With Standard-Dose Bevacizumab for Advanced Solid Tumors for Which Bevacizumab is Indicated

Carboplatin, Bevacizumab and Pemetrexed in the First-Line Treatment of Patients With Malignant Pleural Mesothelioma (MPM)

To Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 386 When Used in Combination With AMG 706, Bevacizumab, Sorafenib, or Sunitinib.

Bevacizumab in Treating Patients With Advanced Solid Tumors

Metronomic

CNTO95/Avastin

Trial of Deforolimus in Combination With Bevacizumab for Patients With Advanced Cancers (8669-010)(COMPLETED)

Bevacizumab, Everolimus, and Erlotinib in Treating Patients With Advanced Solid Tumors

BEP

Bevacizumab and Sunitinib in Treating Patients With Solid Tumors

Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant Mesothelioma

Effect of Bevacizumab and VEGF on Platelet Clustering in Patients Who Are Receiving Bevacizumab for Cancer

Bevacizumab in Treating Young Patients With Refractory Solid Tumors

Enzastaurin and Bevacizumab in Treating Patients With Locally Advanced or Metastatic Cancer

A Phase I Study of ABT-510 in Combination With Bevacizumab in Advanced Solid Tumors

Bortezomib and Docetaxel in Treating Patients With Advanced Solid Tumors

BEL